– Enrollment completed within planned timeframe of 14 months – – IGV-001 granted Fast Track designation by U.S. FDA – – $35 million financing completed in 2024 to fund operations beyond expected Phase 2b data readout in mid-2025 – PHILADELPHIA, May 21, 2024--(BUSINESS WIRE)--Imvax, Inc., a clinical-stage biotechnology...
PHILADELPHIA--(BUSINESS WIRE)-- Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed financing, led by Khosla Ventures, with participation from Kairos Ventures, CS Ventures, MBX Capital, and Bison Ventures. This...
Save the date for another exciting event from BioLabs Philadelphia & BioStrategy Partners! *When: tuesday, november 19th | 3:30pm - 7:00pm Where: the curtis | 601 walnut st. philadelphia, pa 19106 View More Information ...